As anticipated, USP28-depleted melanoma cell lines were more resistant to BRAF inhibitor treatment and then their wild-type counterparts, as demonstrated by a rightward shift in the dose–response curve (Fig. 4, F and G; Fig. S5, A and B). This evidence concerns the gene USP28 and melanoma.